---
title: 'A Systematic Review of Nanomedicine in Glioblastoma Treatment: Clinical Efficacy,
  Safety, and Future Directions'
date: '2023-12-23'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38137175/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20231223170641&v=2.18.0
source: heidelberg[Affiliation]
description: '(1) Background: Glioblastoma (GBM) is categorized as a grade IV astrocytoma
  by the World Health Organization (WHO), representing the most aggressive and prevalent
  form of glioma. It presents a significant clinical challenge, with limited treatment
  options and poor prognosis. This systematic review evaluates the efficacy and safety
  of various nanotherapy approaches for GBM and explores future directions in tumor
  management. Nanomedicine, which involves nanoparticles in the 1-100 nm range, ...'
disable_comments: true
---
(1) Background: Glioblastoma (GBM) is categorized as a grade IV astrocytoma by the World Health Organization (WHO), representing the most aggressive and prevalent form of glioma. It presents a significant clinical challenge, with limited treatment options and poor prognosis. This systematic review evaluates the efficacy and safety of various nanotherapy approaches for GBM and explores future directions in tumor management. Nanomedicine, which involves nanoparticles in the 1-100 nm range, ...